EUVIMEDOtkrijte EUVIMED
Crossref

Outcomes and Tolerability of Early Mammalian Target of Rapamycin Inhibitor Initiation for Renal Sparing in Heart Transplant Recipients

Avery Marcotte, Rachel Rikard, Chelsea Castor, Margeaux Meilhac, Patricia Chang, Mirnela Byku, Christina Teeter Doligalski

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70364 ↗

At a glance

Journal article in Clinical Transplantation, 2025. Written by Avery Marcotte and 6 co-authors. Institution: Department of Pharmacy, UNC Health, Chapel Hill, North Carolina, USA. Major MEDLINE topics: Heart Transplantation, Graft Rejection, MTOR Inhibitors, Immunosuppressive Agents. 14 references.

SažetakSubjectsBibliografski podaciCiteRelated studies

Abstract (original language)

Purpose

Renal dysfunction in heart transplant recipients (HTRs) is a significant post‐transplant complication. This study aims to assess the effects of early mammalian target of rapamycin inhibitor (mTORi) initiation on renal and graft outcomes in HTRs.

Methods

A single‐center retrospective analysis of first‐time adult HTRs transplanted from 2018 to 2023 was conducted. HTRs converted to mTORi were compared to those maintained on tacrolimus and mycophenolate immunosuppression (SOC). Patient demographics along with renal and graft outcomes were collected for the first 2 years post‐transplant.

Results

Eighty‐one HTRs were included; 30 (37%) were initiated on an mTORi. Compared to the SOC group, the mTORi group had a significantly higher improvement in eGFR from 6 to 24 months post‐transplant (36.8% vs. 11.0%, p = 0.027). No cardiac allograft vasculopathy was observed in the mTOR group at 24 months compared to 7 (13.7%) HTRs in the SOC group ( p = 0.03), and there were no differences in treated ACR >30 days post‐transplant, AMR, or DSAs with mTORi versus SOC.

Conclusion

In our experience, early mTORi initiation was associated with renal benefits in HTRs when compared to SOC. Conversion to mTORi allowed for lower tacrolimus levels without an increased risk for rejection or DSAs and was associated with less cardiac allograft vasculopathy at 24 months.

Subjects

MeSH terms (MEDLINE)

Heart TransplantationGraft RejectionMTOR InhibitorsImmunosuppressive AgentsPostoperative ComplicationsHumansFemaleMaleRetrospective StudiesMiddle AgedGraft SurvivalFollow-Up StudiesPrognosisGlomerular Filtration RateRisk FactorsAdultTOR Serine-Threonine KinasesTransplant Recipients

Author keywords

heart transplantimmunosuppressantmechanistic target of rapamycin (mTOR)

Substances

MTOR InhibitorsImmunosuppressive AgentsTOR Serine-Threonine KinasesMTOR protein, human

Authors and institutions

  • Department of Pharmacy, UNC Health, Chapel Hill, North Carolina, USA.
  • UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
  • Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.

Cite

APA

Marcotte, A., Rikard, R., Castor, C., Meilhac, M., Chang, P., Byku, M., & Doligalski, C. T. (2025). Outcomes and Tolerability of Early Mammalian Target of Rapamycin Inhibitor Initiation for Renal Sparing in Heart Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70364

Vancouver

Marcotte A, Rikard R, Castor C, Meilhac M, Chang P, Byku M, et al. Outcomes and Tolerability of Early Mammalian Target of Rapamycin Inhibitor Initiation for Renal Sparing in Heart Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70364

BibTeX
@article{Marcotte2025,
  author = {Marcotte, Avery and Rikard, Rachel and Castor, Chelsea and Meilhac, Margeaux and Chang, Patricia and Byku, Mirnela and Doligalski, Christina Teeter},
  title = {Outcomes and Tolerability of Early Mammalian Target of Rapamycin Inhibitor Initiation for Renal Sparing in Heart Transplant Recipients},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70364}
}
Start for free →